NASDAQ: ERYPErytech Pharma Sa Stock
$0.87-0.07 (-7.45%)
Updated Jun 1, 2023
ERYP Price
$0.87
Fair Value Price
N/A
Market Cap
$27.11M
52 Week Low
$0.30
52 Week High
$1.47
P/E
-79.45x
P/B
1.09x
P/S
0.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$32.98M
Earnings
-$242.55k
Gross Margin
100%
Operating Margin
5.35%
Profit Margin
-0.7%
Debt to Equity
0.95
Operating Cash Flow
-$34M
Beta
0.48
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ERYP Overview
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ERYP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ERYP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ERYP is good value based on its book value relative to its share price (1.09x), compared to the US Biotechnology industry average (5.14x)
P/B vs Industry Valuation
ERYP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ERYP due diligence checks available for Premium users.
Be the first to know about important ERYP news, forecast changes, insider trades & much more!
ERYP News
Valuation
ERYP fair value
Fair Value of ERYP stock based on Discounted Cash Flow (DCF)
Price
$0.87
Fair Value
$2.69
Undervalued by
67.66%
ERYP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ERYP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-79.45x
Industry
11.46x
Market
52.37x
ERYP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.09x
Industry
5.14x
ERYP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ERYP's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ERYP's Earnings (EBIT) of $1.76M... subscribe to Premium to read more.
Interest Coverage Financials
ERYP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$48.7M
Liabilities
$23.7M
Debt to equity
0.95
ERYP's short-term assets ($45.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ERYP's short-term assets ($45.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ERYP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ERYP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ERYP's operating cash flow (-$33.79M)... subscribe to Premium to read more.
Debt Coverage Financials
ERYP vs Biotech Stocks
Erytech Pharma Sa Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.